The effectiveness of radioligand therapy is counterintuitive: as tumors shrink and PSMA binding sites decrease, less radiation is delivered to the cancer. The VISION trial showed the first two doses delivered more radiation to the tumor than the subsequent four, questioning the value of a fixed, prolonged treatment schedule.

The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

Direxonrasib is showing unprecedented response rates (e.g., 47% in frontline) for metastatic pancreatic cancer, a historically difficult-to-treat disease. This high performance prompts comparisons to the targeted therapy successes seen in lung cancer, signaling a potential paradigm shift in treatment expectations for PDAC.

TAMP is delivered once every two weeks, but crucially, patients generally do not receive other treatments concurrently. This regimen provides significant breaks from therapy, helping to preserve pre-procedural quality of life—a major advantage over the continuous burden of systemic chemotherapy.

Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.

TAMP uses a unique double-balloon catheter to isolate an arterial segment. This pressure-mediated delivery forces chemotherapy across the vessel wall directly into the tumor, overcoming the washout effect that caused previous intra-arterial therapies to fail.

Despite pancreatic cancer being notoriously difficult, Actuate prioritized it as a lead indication for strategic reasons. Strong preclinical data allowed the company to bypass later-line trials and move directly into a first-line setting, a 'leapfrog' maneuver that significantly accelerates the drug's overall development and regulatory path.

Historically, intratumoral therapy was limited by the physical difficulty of reaching tumors. The rise of a new discipline, Interventional Oncology, has largely solved this access problem. The critical bottleneck is now the lack of drugs specifically designed and optimized for local delivery and sustained retention within the tumor.

Clinical data revealed a surprising synergy: patients receiving TAMP after chemoradiation had a 60% two-year survival rate. The theory is that radiation remodels the tumor's microvasculature, reducing drug washout and effectively 'priming' the tumor for this regional therapy.